You are here

  • Home
  • Archive
  • Volume 4, Issue 6
  • Acarbose was effective in maintaining glycemic control in type 2 diabetes mellitus but was associated with adverse effects

Article Text

Article menu
Therapeutics
Acarbose was effective in maintaining glycemic control in type 2 diabetes mellitus but was associated with adverse effects

https://doi.org/10.1136/ebm.4.6.189

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Holman RR, Cull CA, Turner RC, on behalf of the UKPDS Study Group. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care. 1999 Jun; 22:960-4.

    Question

    What is the effectiveness of acarbose for maintaining glycemic control in patients receiving established therapy for type 2 diabetes mellitus?

    Design

    Randomized (concealed), double-blind, placebo-controlled trial with follow-up of 3 years.

    Setting

    23 hospital-based diabetes clinics in the United Kingdom.

    Patients

    1946 patients (mean age 60 y, 63% men, mean body mass index 30 kg/m2, median hemoglobin [Hb] A1c level 7.9%, median fasting plasma glucose [FPG] level 8.7 mmol/L) who had type 2 diabetes, were already receiving therapy, and did not have gastrointestinal problems or life-threatening illness. Follow-up was 83%.

    Intervention

    Patients were allocated to acarbose (n = 973), titrated to a maximum dose of 100 mg 3 times/d, or placebo (n …

    View Full Text